Ashvattha Therapeutics Announces $69 Million in Series B Fin

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

China , Malaysia , Huadong , Guangdong , Singapore , Jeffrey Cleland , Kannan Rangaramanujam , Jordyn Temperato , Lifesci Communications , Huadong Medicine Investment Holding Co Ltd , Natural Capital Investment Fund , Sujatha Kannan At Johns Hopkins University , Seriesb Financing , Plum Alley Investments , Tribe Capital , Natural Capital , Plum Alley , Huadong Medicine , Sujatha Kannan , Johns Hopkins , Resume , Careers , Shvattha Therapeutics Announces 69 Million In Seriesb Financing And Up To 45m Exclusive License Agreement With Huadong Advance Hydroxyl Dendrimer Based Precision Medicines , Iospace , Advice ,